I

[illegible]

[illegible] (I[illegible]) [illegible] 1 [illegible] 2 [illegible]

C[illegible] D[illegible] E

[illegible] 3 [illegible] (I[illegible] 1). [illegible]

[illegible]

T[illegible] 4 [illegible] 2 [illegible] 2 [illegible]

E

3

T

.103 T 0.003

C

[illegible]

References

1. Behrens A, Doyle JJ, Stern L (2006) Dysfunctional tear syndrome: A Delphi approach to treatment recommendations. Cornea 25: 900–907.
2. O'Brien PD, Collum LMT (2004) Dry eye: diagnosis and current treatment strategies. Curr Allergy Asthma Rep 4: 314–319.
3. Nakamura H, Kawakami A, Eguchi K (2006) Mechanisms of autoantibody production and the relationship between autoantibodies and the clinical manifestations in Sjogren's syndrome. Transl Res 148: 281–288.
4. Vitali C, Bombardieri S, Jonsson R (2002) Classifcation criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558.
5. Smith JA, Albenz J, Begley C (2007) The epidemiology of dry eye disease: report of the epidemiology subcommittee of the international Dry Eye Workshop (2007). Ocul Surf 5: 93–107.
6. Miljanovic B, Dana R, Sullivan DA, Schaumberg DA (2007) Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol 143: 409–415.
7. Schaumberg DA, Sullivan DA, Buring JE, Dana MR (2003) Prevalence of dry eye syndrome among US women. Am J Ophthalmol 136: 318–326.
8. Schaumberg DA, Sullivan DA, Dana MR (2002) Epidemiology of dry eye syndrome. Adv Exp Med Biol 506: 989–998.
9. Moss SE, Klein RK, Klein BEK (2000) Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol 118: 1264–1268.
10. Gayton JL (2009) Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol 3: 405–412.

11.Etiology, prevalence,12.S, DA, Bu, GuTw DA, Bberg.62 0Auchi K (2007)annu inteA, Ec